Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
Status:
Completed
Trial end date:
2004-05-07
Target enrollment:
Participant gender:
Summary
The goal of this research is to see if giving the drug SCH66336 by mouth can improve the
disease in patients with chronic or accelerated phase CML. The safety of this treatment will
also be studied.